PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/695, 31/12 — A1

(11) International Publication Number: WO 00/56341

(43) International Publication Date: 28 September 2000 (28.09.00)

(21) International Application Number: PCT/GB00/01086

(22) International Filing Date: 22 March 2000 (22.03.00)

(30) Priority Data:

9906587.2	22 March 1999 (22.03.99)	GB
60/126,968	30 March 1999 (30.03.99)	US

(71) Applicant *(for all designated States except US)*: CHARTERHOUSE THERAPEUTICS LTD. [GB/GB]; 15 City Business Centre, Hyde Street, Winchester, Hampshire S023 7TA (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: SANTORO, Maria, Gabriella [IT/IT]; Department of Biology, University of Rome, Tor Vergata, Via della Ricerca Scientifica, I–00133 Rome (IT). ROBERTS, Stanley, Michael [GB/GB]; The University of Liverpool, The Robert Robinson Laboratories, Liverpool L69 7ZD (GB). GUYOT, Thierry [FR/GB]; Tocris Cookson Ltd., Northpoint, Fourth Way, Avonmouth, Bristol BS11 8TA (GB).

(74) Agents: WHITE, Martin, Paul et al.; Fry Heath & Spence, The Old College, 53 High Street, Horley, Surrey RH6 7BN (GB).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: CHEMICAL COMPOUNDS AND THEIR USES

(57) Abstract

4– and 5–oxacyclopent–2–en–1–ones have significant activity in activating HSF and in inhibiting NF–κB. They are believed to be useful in treating a wide range of disorders including viral–mediated disorders, bacterial–mediated disorders, disorders mediated by radiation (e.g. by UV–radiation), inflammatory disorders, disorders of the immune system, ischemia, arteriosclerosis, disorders involving cell proliferation (e.g. cancers), disorders involving damage to, or killing of cells (e.g. oxidative cell damage) and diabetes.